Stanton Marshall S., Senior Vice President of Clinical & Medical Affairs, has demonstrated a clear selling bias in his recent trading activity involving Artivion, Inc. (AORT), according to SEC Form 4 filings. Over 36 reported transactions, Marshall has sold approximately $4.54 million worth of AORT shares while purchasing just $926,167.86—a nearly 5-to-1 ratio favoring disposals. His most recent sales occurred on March 2–3, 2026, totaling $138,711.43, following earlier disposals in late February 2026 worth $136,013.21. The bulk of his selling activity, however, clustered in November 2025, with six transactions on November 20–21 alone accounting for over $2.5 million in proceeds, including a single $840,041.55 sale.
Marshall’s transactions show a pattern of concentrated disposals, often executed in multiple blocks within short timeframes. For example, his November 2025 sales included five separate dispositions totaling $2.57 million across two days, supplemented by smaller sales earlier that month. While some filings reflect stock awards (coded "A") or option exercises (coded "M"), the overwhelming majority are outright sales (coded "S"). Notably, Marshall has not reported any purchases since at least early 2025, with his last acquisition predating the available data. The consistency and scale of these disposals suggest an ongoing reduction in his AORT position, though the filings do not indicate whether these sales represent planned divestments or discretionary trades.
AI-assisted summary